MedicaidPrior AuthMedium impact
Parsabiv® (etelcalcetide) intravenous solution (New)
Humana·LA · Nephrology, Internal Medicine·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Louisiana Medicaid has established a new prior authorization policy for Parsabiv (etelcalcetide) intravenous solution, effective March 1, 2026. This medication requires prior approval for adult hemodialysis patients with secondary hyperparathyroidism due to chronic kidney disease, with specific clinical criteria including age ≥18, corrected serum calcium ≥8.3 mg/dL, and previous treatment with generic vitamin D analogs.
Action Required
Before March 1, 2026: Clinical staff must implement prior authorization workflow for Parsabiv (etelcalcetide) for Louisiana Medicaid patients. Verify patients meet all criteria: age ≥18, secondary hyperparathyroidism with CKD on hemodialysis, corrected serum calcium ≥8.3 mg/dL, and prior treatment with generic vitamin D analogs. Update EMR templates to capture required clinical documentation. Claims will be denied without proper prior authorization.